Efficacy of La Roche Posay Routine in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP)

Launched by COSMETIQUE ACTIVE INTERNATIONAL · Jan 7, 2025

Keywords

ClinConnect Summary

The sample size of this study is 80 participants; 40 subjects testing Niacinamide A serum and UV Mune and 40 subjects testing Eucerin Thiamidol anti-pigment serum and Eucerin SPF 50+. The secondary objectives are:

* the effect on the cutaneous acceptability by clinical examination under dermatological control
* the effect of the product on acne lesions is assessed by comparing the number of elements on the face before application and after product use
* the effect on acne severity according to the Global Acne Evaluation
* the mean darkness of the post-inflammatory hyper-pigmentation (PIHP)...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fitzpatrick skin phototype: III to VI;
• • Moderate to severe PIHP due to acne (score PAHPI \> 10);
• • Subjects with mild acne on the face (GEA = 2);
• • ≤ 4 inflammatory lesions total (non-inflammatory lesions could be 0)
• Exclusion Criteria:
• • Subjects with symptoms of COVID-19 (moderate fever, dry cough and other symptoms described by the World Health Organization);
• • Subjects with a temperature above 37.5 °C;
• • COVID-19 positive patients;
• • For women: pregnant or nursing woman or woman planning to get pregnant during the study;
• • Cutaneous pathology on the study zone (eczema, etc);
• • Use of topical or systemic treatment (for ex: treatment of acne) during the previous weeks liable to interfere with the assessment of the cutaneous acceptability/efficacy of the study product;
• • Subject with make-up products on the day of the visit at the laboratory;
• * Acne and depigmenting treatment (topical or systemic):
• • Topical treatment claiming depigmenting effect of the face: within the last month,
• • Facial procedures: within the last 3 months,
• • Systemic retinoid: within the last 6 months.
• • Cosmetic product for non-comedogenicity within the last 2 weeks;
• • Subjects treated for PIHP within the past 3 months with either a cosmetic product or a drug;
• • Any change in hormonal treatment (including contraceptive) during the three previous months of the study;
• • Subject having undergone a surgery under general anesthesia within the previous month;
• • Excessive exposure to sunlight or UV-rays within the previous month;
• • Subject enrolled in another clinical trial during the study period.